Overview

Acute Effects of R- and S-MDMA in Healthy Subjects

Status:
Not yet recruiting
Trial end date:
2023-12-31
Target enrollment:
Participant gender:
Summary
Racemic ±3,4-methylenedioxymethamphetamine (MDMA) is a psychoactive substance and prototypical empathogen acutely inducing feelings of heightened mood, empathy, trust and closeness to others. These acute subjective effects of MDMA may be helpful to assist psychotherapy and MDMA is currently investigated in phase 3 trials as a possible treatment in post-traumatic stress disorder.
Phase:
Phase 1
Details
Lead Sponsor:
University Hospital, Basel, Switzerland
Treatments:
N-Methyl-3,4-methylenedioxyamphetamine